Plain-English translation of NCT04861558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a treatment called hyperthermic intraperitoneal chemotherapy (HIPEC), which delivers heated chemotherapy directly into your abdomen during surgery to treat colorectal cancer that has spread to the lining of your belly. Researchers want to compare two different approaches: a standard dose and a more intensive dose with additional medication given after surgery. The goal is to see which approach works best and is safest for patients like you.
When colorectal cancer spreads to the abdominal lining, it's very difficult to treat with standard chemotherapy alone. This trial exists to find out whether delivering heated chemotherapy directly to the affected area during surgery—rather than through the bloodstream—can improve survival and quality of life for patients with this advanced form of cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo surgery to remove as much cancer as possible from your abdomen. During that same surgery, you will receive one of two versions of heated chemotherapy treatment directly into your abdominal cavity—either the standard dose or a more intensive dose. If you receive the intensive version, additional chemotherapy will be given through small drains left in your abdomen after surgery is complete, usually for 5 days. Your doctors will monitor you closely during recovery to watch for side effects and to measure how well the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
India
Sweden